FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186390717> ?p ?o ?g. }

• W3186390717 endingPage "352" @default.
• W3186390717 startingPage "343" @default.
• W3186390717 abstract "Due to the high incidence and mortality of lung cancer, and etoposide is the standard first-line chemotherapy for small cell lung cancer, to evaluate the efficacy and safety of etoposide capsules at different doses as maintenance therapy for patients with extensive-stage small cell lung cancer (ES-SCLC) who show a response to etoposide plus platinum.The study was divided into two stages: stage I, a single-center, one-arm prospective study, and stage II, a multicenter, controlled non-randomized prospective study (patients were chosen from ClinicalTrials.gov Identifier: NCT02179528). All patients received six cycles of etoposide plus platinum. Patients who were evaluated as complete remission (CR) or partial remission (PR) entered the maintenance treatment (MT) (etoposide capsule, once a day for 20 days, every 28 days as a cycle, until disease progression). In stage I, the dose of etoposide was 25 mg; in stage II, patients were non-randomized into etoposide capsule (25 mg/50 mg) and observation groups. In this study, the primary endpoints were progression-free survival (PFS) and safety; the secondary endpoint was overall survival (OS). Toxicity was graded according to the Common Terminology Criteria for Adverse Events v3.0.Ninety-two patients were enrolled. In stage I, the median PFS was 6.700 months (95% CI: 6.408-6.992). In stage II, the median PFS of the MT group was better than that in the NMT group (8.930 vs. 5.900 months, P=0.002). In the pooled analysis, the overall median PFS of the MT group was better than that of the NMT group (7.870 vs. 5.900 months, P=0.003). However, there was no significant difference in OS between the groups (15.030 vs. 14.330 months, P=0.813). Multivariate Cox regression analysis showed that maintenance therapy was an independent protective factor for PFS in patients with ES-SCLC.Etoposide capsules as maintenance therapy significantly prolonged the PFS of patients with ES-SCLC who responded to etoposide plus platinum, with acceptable tolerability." @default.
• W3186390717 created "2021-08-02" @default.
• W3186390717 creator A5000728919 @default.
• W3186390717 creator A5003002891 @default.
• W3186390717 creator A5015860750 @default.
• W3186390717 creator A5018396032 @default.
• W3186390717 creator A5046597133 @default.
• W3186390717 creator A5047551110 @default.
• W3186390717 creator A5064970901 @default.
• W3186390717 creator A5067911307 @default.
• W3186390717 creator A5070186527 @default.
• W3186390717 creator A5075877965 @default.
• W3186390717 creator A5079124416 @default.
• W3186390717 creator A5086753069 @default.
• W3186390717 creator A5091885695 @default.
• W3186390717 date "2021-01-01" @default.
• W3186390717 modified "2023-09-25" @default.
• W3186390717 title "The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: a prospective two-stage, two-center study" @default.
• W3186390717 cites W1930864136 @default.
• W3186390717 cites W2007407440 @default.
• W3186390717 cites W2337845807 @default.
• W3186390717 cites W2586697182 @default.
• W3186390717 cites W2597133748 @default.
• W3186390717 cites W2780875731 @default.
• W3186390717 cites W2789179380 @default.
• W3186390717 cites W2804157113 @default.
• W3186390717 cites W2804287047 @default.
• W3186390717 cites W2886615577 @default.
• W3186390717 cites W2888722423 @default.
• W3186390717 cites W2893960509 @default.
• W3186390717 cites W2894628523 @default.
• W3186390717 cites W2906939357 @default.
• W3186390717 cites W2912936747 @default.
• W3186390717 cites W2950885793 @default.
• W3186390717 cites W2950955057 @default.
• W3186390717 cites W2968594753 @default.
• W3186390717 cites W2971309637 @default.
• W3186390717 cites W2977392388 @default.
• W3186390717 cites W2990015261 @default.
• W3186390717 cites W2994790991 @default.
• W3186390717 cites W3005098883 @default.
• W3186390717 cites W3014239697 @default.
• W3186390717 cites W3030178583 @default.
• W3186390717 doi "https://doi.org/10.21037/jtd-21-106" @default.
• W3186390717 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7867853" @default.
• W3186390717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33569214" @default.
• W3186390717 hasPublicationYear "2021" @default.
• W3186390717 type Work @default.
• W3186390717 sameAs 3186390717 @default.
• W3186390717 citedByCount "1" @default.
• W3186390717 countsByYear W31863907172022 @default.
• W3186390717 crossrefType "journal-article" @default.
• W3186390717 hasAuthorship W3186390717A5000728919 @default.
• W3186390717 hasAuthorship W3186390717A5003002891 @default.
• W3186390717 hasAuthorship W3186390717A5015860750 @default.
• W3186390717 hasAuthorship W3186390717A5018396032 @default.
• W3186390717 hasAuthorship W3186390717A5046597133 @default.
• W3186390717 hasAuthorship W3186390717A5047551110 @default.
• W3186390717 hasAuthorship W3186390717A5064970901 @default.
• W3186390717 hasAuthorship W3186390717A5067911307 @default.
• W3186390717 hasAuthorship W3186390717A5070186527 @default.
• W3186390717 hasAuthorship W3186390717A5075877965 @default.
• W3186390717 hasAuthorship W3186390717A5079124416 @default.
• W3186390717 hasAuthorship W3186390717A5086753069 @default.
• W3186390717 hasAuthorship W3186390717A5091885695 @default.
• W3186390717 hasBestOaLocation W31863907171 @default.
• W3186390717 hasConcept C126322002 @default.
• W3186390717 hasConcept C141071460 @default.
• W3186390717 hasConcept C146357865 @default.
• W3186390717 hasConcept C151730666 @default.
• W3186390717 hasConcept C168563851 @default.
• W3186390717 hasConcept C188816634 @default.
• W3186390717 hasConcept C197934379 @default.
• W3186390717 hasConcept C203092338 @default.
• W3186390717 hasConcept C2776256026 @default.
• W3186390717 hasConcept C2776694085 @default.
• W3186390717 hasConcept C2777793932 @default.
• W3186390717 hasConcept C2778119113 @default.
• W3186390717 hasConcept C71924100 @default.
• W3186390717 hasConcept C86803240 @default.
• W3186390717 hasConceptScore W3186390717C126322002 @default.
• W3186390717 hasConceptScore W3186390717C141071460 @default.
• W3186390717 hasConceptScore W3186390717C146357865 @default.
• W3186390717 hasConceptScore W3186390717C151730666 @default.
• W3186390717 hasConceptScore W3186390717C168563851 @default.
• W3186390717 hasConceptScore W3186390717C188816634 @default.
• W3186390717 hasConceptScore W3186390717C197934379 @default.
• W3186390717 hasConceptScore W3186390717C203092338 @default.
• W3186390717 hasConceptScore W3186390717C2776256026 @default.
• W3186390717 hasConceptScore W3186390717C2776694085 @default.
• W3186390717 hasConceptScore W3186390717C2777793932 @default.
• W3186390717 hasConceptScore W3186390717C2778119113 @default.
• W3186390717 hasConceptScore W3186390717C71924100 @default.
• W3186390717 hasConceptScore W3186390717C86803240 @default.
• W3186390717 hasIssue "1" @default.
• W3186390717 hasLocation W31863907171 @default.
• W3186390717 hasLocation W31863907172 @default.
• W3186390717 hasLocation W31863907173 @default.

• next